COVID-19: A Catalyst for Transforming Randomized Trials. Issue 1 (1st January 2022)

• Record Type: Journal Article
• Authors: Lee, Jennifer J.; Price, Jerri C.; Jackson, William M.; Whittington, Robert A.; Ioannidis, John P.A.
• Is Part Of: Journal of neurosurgical anesthesiology. Volume 34:Issue 1(2022)
• Page Start: 107
• Page End: 112
• Publication Date: 2022-01-01
• Subjects: COVID-19 -- SARS-CoV-2 -- pandemic -- clinical trials -- research design; Anesthesia in neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; 617.96748
• DOI: 10.1097/ANA.0000000000000804
• Languages: English
• ISSNs: 0898-4921

Abstract

Abstract : The coronavirus disease 2019 (COVID-19) pandemic incited a global clinical trial research agenda of unprecedented speed and high volume. This expedited research activity in a time of crisis produced both successes and failures that offer valuable learning opportunities for the scientific community to consider. Successes include the implementation of large adaptive and pragmatic trials as well as burgeoning efforts toward rapid data synthesis and open science principles. Conversely, notable failures include: (1) inadequate study design and execution; (2) data reversal, fraud, and retraction; and (3) research duplication and waste. Other challenges that became highlighted were the need to find unbiased designs for investigating complex, nonpharmaceutical interventions and the use of routinely collected data for outcomes assessment. This article discusses these issues juxtaposing the COVID-19 trials experience against trials in anesthesiology and other fields. These lessons may serve as a positive catalyst for transforming future clinical trial research.